Board Meeting

LINCOLN PHARMACEUTICALS LTD.

NSE : LINCOLNBSE : 531633ISIN CODE : INE405C01035Industry : Pharmaceuticals & DrugsHouse : Private
BSE600.402.15 (+0.36 %)
PREV CLOSE ( ) 598.25
OPEN PRICE ( ) 609.05
BID PRICE (QTY) 598.55 (9)
OFFER PRICE (QTY) 600.35 (12)
VOLUME 915
TODAY'S LOW / HIGH ( )596.60 609.05
52 WK LOW / HIGH ( )365.4 754.25
NSE600.450.7 (+0.12 %)
PREV CLOSE( ) 599.75
OPEN PRICE ( ) 605.05
BID PRICE (QTY) 600.35 (1)
OFFER PRICE (QTY) 601.35 (1)
VOLUME 3053
TODAY'S LOW / HIGH( ) 597.55 605.05
52 WK LOW / HIGH ( )365.25 755.15

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.